

1 Novel small RNAs expressed by *Bartonella bacilliformis* under multiple conditions  
2 reveal potential mechanisms for persistence in the sand fly vector and human  
3 host

4

5

6 Shaun Wachter<sup>1</sup>, Linda D. Hicks<sup>1</sup>, Rahul Raghavan<sup>2</sup> and Michael F. Minnick<sup>1\*</sup>

7

8

9

10 <sup>1</sup> Program in Cellular, Molecular & Microbial Biology, Division of Biological Sciences,  
11 University of Montana, Missoula, Montana, United States of America

12 <sup>2</sup> Department of Biology and Center for Life in Extreme Environments, Portland State  
13 University, Portland, Oregon, United States of America

14

15

16

17 \* Corresponding author

18 E-mail: [mike.minnick@mso.umt.edu](mailto:mike.minnick@mso.umt.edu) (MFM)

19

20

## 21 **Abstract**

22 *Bartonella bacilliformis*, the etiological agent of Carrión's disease, is a Gram-negative,  
23 facultative intracellular alphaproteobacterium. Carrión's disease is an emerging but neglected  
24 tropical illness endemic to Peru, Colombia, and Ecuador. *B. bacilliformis* is spread between  
25 humans through the bite of female phlebotomine sand flies. As a result, the pathogen encounters  
26 significant and repeated environmental shifts during its life cycle, including changes in pH and  
27 temperature. In most bacteria, small non-coding RNAs (sRNAs) serve as effectors that may post-  
28 transcriptionally regulate the stress response to such changes. However, sRNAs have not been  
29 characterized in *B. bacilliformis*, to date. We therefore performed total RNA-sequencing  
30 analyses on *B. bacilliformis* grown *in vitro* then shifted to one of ten distinct conditions that  
31 simulate various environments encountered by the pathogen during its life cycle. From this, we  
32 identified 160 sRNAs significantly expressed under at least one of the conditions tested. sRNAs  
33 included the highly-conserved tmRNA, 6S RNA, RNase P RNA component, SRP RNA  
34 component, *ffh* leader RNA, and the alphaproteobacterial sRNAs  $\alpha$ 45 and *speF* leader RNA. In  
35 addition, 153 other potential sRNAs of unknown function were discovered. Northern blot  
36 analysis was used to confirm the expression of eight novel sRNAs. We also characterized a  
37 *Bartonella bacilliformis* **group I** intron (BbgpI) that disrupts an un-annotated tRNA<sub>CCU</sub><sup>Arg</sup> gene  
38 and determined that the intron splices *in vivo* and self-splices *in vitro*. Furthermore, we  
39 demonstrated the molecular targeting of *Bartonella bacilliformis* **small RNA 9** (BbsR9) to  
40 transcripts of the *ftsH*, *nuoF*, and *gcvT* genes, *in vitro*.

## 41 **Author summary**

42 *B. bacilliformis* is a bacterial pathogen that is transmitted between humans by  
43 phlebotomine sand flies. Bacteria often express sRNAs to fine-tune the production of proteins

44 involved in a wide array of biological processes. We cultured *B. bacilliformis* *in vitro* under  
45 standard conditions then shifted the pathogen for a period of time to ten distinct environments,  
46 including multiple temperatures, pH levels, and infections of human blood and human vascular  
47 endothelial cells. After RNA-sequencing, a manual transcriptome search identified 160 putative  
48 sRNAs, including seven highly-conserved sRNAs and 153 novel potential sRNAs. We then  
49 characterized two of the novel sRNAs, BbgpI and BbsR9. BbgpI is a group I intron (ribozyme)  
50 that self-splices and disrupts an unannotated gene coding for a transfer RNA (tRNA<sub>CCU</sub><sup>Arg</sup>).  
51 BbsR9 is an intergenic sRNA expressed under conditions that simulate the sand fly. We found  
52 that BbsR9 targets transcripts of the *ftsH*, *nuoF*, and *gcvT* genes. Furthermore, we determined the  
53 specific sRNA-mRNA interactions responsible for BbsR9 binding to its target mRNAs through  
54 *in vitro* mutagenesis and binding assays.

55

## 56 **Introduction**

57 *Bartonella bacilliformis* is a Gram-negative, facultative intracellular bacterium and the  
58 etiological agent of Carrión's disease in humans. Carrión's disease often manifests as a biphasic  
59 illness characterized by acute hemolytic anemia followed by eruptions of blood-filled  
60 hemangiomas of the skin [1]. Timely antibiotic administration restricts the fatality rate of  
61 Carrión's disease to ~10%, although if left untreated, the rate has been reported to be as high as  
62 88% [2, 3]. *B. bacilliformis* is transmitted between humans through the bite of female  
63 phlebotomine sand flies, specifically *Lutzomyia* spp. [4, 5]. The endemic region of Carrión's  
64 disease has historically been limited to arid, high-altitude valleys (600 – 3200m) in the Andes  
65 Mountains of Peru, Colombia, and Ecuador, reflecting the habitat of the sand fly vector [6, 7].

66 The initial, acute stage of Carrión’s disease is referred to as Oroya fever (OF), and it is  
67 characterized by colonization of the entire circulatory system, leading to infection of ~61% of all  
68 circulating erythrocytes [7, 8]. This bacterial burden typically leads to severe anemia, fever,  
69 jaundice, and hepatomegaly, among other symptoms [9]. Weeks or months following OF, *B.*  
70 *bacilliformis* seemingly invades endothelial cells, where it triggers cell proliferation and  
71 angiogenesis. This event leads to formation of blood-filled blisters of the skin, referred to as  
72 verruga peruana (VP). The VP stage is chronic and lasts about one month to a year [1, 6].  
73 Although Carrión’s disease can present as a severe illness, there are many documented cases  
74 with relatively milder symptoms and/or the onset of VP without having presented with OF  
75 symptoms [10]. In consideration of reports involving less virulent *B. bacilliformis* strains and the  
76 possibility that other *Bartonella* spp. can cause mild symptoms resembling Carrión’s disease, the  
77 incidence of the disease is likely underreported [11-13].

78 The *B. bacilliformis* infection cycle is strikingly under-studied compared to other vector-  
79 borne pathogens. It is clear that the bacterium is transmitted by *L. verrucarum* sand flies,  
80 although artificial feeding experiments showed that *L. longipalpis* can also “vector” the pathogen  
81 in the laboratory [5]. These studies also revealed that *B. bacilliformis* colonized and persisted in  
82 the lumen of the abdominal midgut of *L. verrucarum* but were digested along with the blood  
83 meal in *L. longipalpis* [5]. Despite this, viable bacteria were retrieved from both insects  
84 following a 7-d colonization period [5]. Other *Lutzomyia* spp. have been found to contain *B.*  
85 *bacilliformis* DNA, but colonization experiments have not been performed [14]. It has also been  
86 suggested that other mammals may serve as reservoir hosts for *B. bacilliformis*. However,  
87 serosurveys of animals that came into contact with infected humans were negative for *B.*  
88 *bacilliformis* DNA [15]. Interestingly, in various attempts to establish an animal model of *B.*

89 *bacilliformis* infection, the bacterium was only able to infect rhesus macaques [16] and owl  
90 monkeys [17]. These results suggest that other primates could conceivably serve as natural  
91 reservoir hosts for *B. bacilliformis*, although there is a paucity of non-human primate species in  
92 *L. verrucarum*'s geographic range. Regardless, the lack of a small animal model severely limits  
93 the prospects of laboratory studies examining *B. bacilliformis* infections *in vivo*.

94 A number of virulence attributes are involved in *B. bacilliformis* pathogenesis, including  
95 erythrocyte attachment [18], invasion [19-21] and hemolysis [22]. Similarly, several factors have  
96 been implicated in endothelial cell invasion [23] and proliferation [24-26]. However, regulatory  
97 mechanisms that facilitate the pathogen's virulence, colonization, and persistence in the sand fly  
98 have not been explored, to date. The disparate environments encountered by *B. bacilliformis*  
99 during transmission from sand fly vector to human host, and back again, suggest that genetic  
100 regulatory mechanisms are used to rapidly adapt to prevailing conditions. For example, the  
101 temperature of the sand fly vector would be comparable to ambient temperatures in the  
102 geographical range of the insect. The competent vector, *L. verrucarum*, is endemic to high-  
103 elevation ranges of the Occidental and Inter-Andean valleys of Peru, Colombia, and Ecuador  
104 [27], where temperatures range from 17°C - 22°C; fairly consistent with laboratory "room  
105 temperature" [28]. Upon transmission to the human host, the bacterium would need to adjust to a  
106 human body temperature of ~37°C. Similarly, human blood has a pH of ~7.4, while the pH of the  
107 sand fly (*L. longipalpis*) abdominal midgut after a blood meal is ~8.2, lowers to ~7.7 as the blood  
108 meal is digested, and decreases to ~6.0 after digestion [29, 30]. In contrast, the thoracic midgut is  
109 maintained at pH ~6.0, regardless of digestion status [29]. A rapid means of regulating virulence  
110 and stress-related factors to counteract sudden shifts in temperature and pH would be clearly  
111 adaptive for *B. bacilliformis*.

112 Bacteria often utilize small RNAs (sRNAs) to rapidly and efficiently regulate gene  
113 products involved in multiple biological processes. sRNAs are small (< 500 nts) non-coding  
114 transcripts that typically serve to up- or down-regulate translation of proteins by binding to the  
115 respective mRNA in a *cis* or *trans* fashion [reviewed in [31]]. This fine-tuning of protein  
116 production can enhance tolerance to stressors, including temperature [32] and pH [33]. To our  
117 knowledge, sRNA research in *Bartonella* is represented by a single report on *B. henselae* [34].  
118 We therefore utilized total RNA-Sequencing (RNA-Seq) to interrogate *B. bacilliformis*  
119 transcriptomes to identify sRNAs expressed under a variety of conditions, including  
120 temperatures and pH levels consistent with the sand fly vector and human host. In doing so, we  
121 discovered 153 novel sRNAs expressed under at least one of the conditions tested. Furthermore,  
122 we characterized two of the sRNAs. The first RNA is a group I intron related to similar elements  
123 found in other alphaproteobacteria, while the other is a novel *Bartonella*-specific sRNA  
124 expressed only under conditions that simulate the sand fly vector.

125

## 126 **Materials and methods**

### 127 **Bacterial culturing**

128 Bacterial strains, primers, and plasmids utilized in this study are described in **S1 Table**. *B.*  
129 *bacilliformis* strain KC583 (passages #4-7) was cultivated on HIBB plates, comprised of Bacto  
130 heart infusion agar (Becton Dickinson; Franklin Lakes, NJ) containing 4% defibrinated sheep  
131 blood and 2% sheep serum (Quad Five, Ryegate, MT), by volume, as previously described [26].  
132 Following 4 d of growth, 4 confluent *B. bacilliformis* plates per biological replicate were either  
133 shifted to different temperatures for 2 h, harvested and shifted to different pH levels in an HIBB

134 liquid medium for 2 h, harvested and shifted to a human blood sample for 2 h, or harvested and  
135 used to infect cultured human umbilical vein endothelial cells (HUVECs; PCS-100-013;  
136 American Type Culture Collection; Manassas, VA) for 24 h. *Escherichia coli* (TOP10) was  
137 grown for 16 h at 37°C with shaking in lysogeny broth (LB), or on LB plates, supplemented with  
138 kanamycin (25 µg/ml) and ampicillin (100 µg/ml), when required.

### 139 **HUVEC culturing and infection**

140 HUVECs were cultured and maintained as previously described [26]. *B. bacilliformis* infections  
141 were carried out for 24 h after which the medium was removed and cells were treated with  
142 gentamicin (10 µg/ml) for 1 h. Remaining viable extracellular *B. bacilliformis* cells were  
143 removed by washing 5 times for 10 min with phosphate-buffered saline (PBS; pH 7.4) solution.  
144 Finally, cells were harvested into TRI Reagent (Ambion; Austin, TX), as previously described  
145 for infected Vero cells [35].

### 146 **Human blood infection**

147 Blood was drawn into vials containing sodium citrate to prevent coagulation. 1-ml aliquots were  
148 dispensed into fresh tubes, after which the lids were replaced with gas-permeable membranes.  
149 Blood samples were equilibrated at 37°C (HB37 samples) or 37°C in a blood-gas atmosphere  
150 (HBBG samples) for 1 h. Four HIBB plates of confluent *B. bacilliformis* for each equilibrated  
151 blood vial were harvested into PBS, pelleted at 16,000 x g for 5 min at 4°C and washed twice in  
152 PBS with identical centrifugation steps. Cell pellets were resuspended into 300 µl equilibrated  
153 blood, then dispensed back into the corresponding tube. The tubes were incubated at the  
154 appropriate condition for 2 h, then 1 ml RNALater solution (Thermo Fisher; Waltham, MA) was  
155 immediately added. Total RNA extraction was done as described below.

## 156 **Total RNA/genomic DNA isolation and preparation for RNA-Seq**

157 Upon shifting *B. bacilliformis* for the designated time periods, cells were either harvested  
158 directly into one volume of RNeasy lysis solution (Qiagen) or centrifuged at 10,000 x g at  
159 room temperature for 2 min, after which the pellet was resuspended in a volume of RNeasy lysis  
160 solution. The cells were incubated at room temperature for 1 h then frozen at -80°C for  $\geq 2$  h. The cells  
161 were thawed, centrifuged at 10,000 x g at 4°C for 10 min, and resuspended in 1 ml of TRI  
162 Reagent (Sigma-Aldrich; St. Louis, MO). The cells were incubated at room temperature for 1 h  
163 then frozen at -80°C for  $\geq 2$  h. Finally, cells were thawed and total RNA and genomic DNA  
164 isolation were done as previously described [35]. Total RNA pools from human blood infections  
165 were globin-depleted using a GLOBINclear kit (Ambion) according to manufacturer's  
166 specifications. HUVE, HB37, and HBBG samples were enriched for bacterial RNA using a  
167 MICROBEnrich kit (Ambion). RNA (1  $\mu$ g) from three independent biological replicates of each  
168 condition was sent to the Yale Center for Genomic Analysis (PI25, PI30, PI37, pH06, pH07, and  
169 pH08 samples) or GENEWIZ (PIBG, HUVE, HB37, and HBBG samples) for bacterial rRNA  
170 depletion, stranded-library preparation, and HiSeq2500 (Illumina; San Diego, CA) 2x150 bp  
171 sequencing.

## 172 **Data analysis**

173 Raw reads were quality filtered and aligned as previously described [35]. Briefly, raw fastq files  
174 were concatenated, quality filtered with the FASTX toolkit  
175 ([http://hannonlab.cshl.edu/fastx\\_toolkit/](http://hannonlab.cshl.edu/fastx_toolkit/)), and then clipped, aligned, and filtered with Neson  
176 version 0.128 tools (<http://www.vicbioinformatics.com/software.nesoni.shtml>). Transcripts per  
177 million (TPM) were calculated using a custom Python script that can be accessed through



178 GitHub ([https://github.com/shawachter/TPM\\_Scripts](https://github.com/shawachter/TPM_Scripts)). Stranded alignments were separated using  
179 SAMtools [36] and visualized using the Artemis genome browser [37].

180 sRNA identification was performed using the Artemis genome browser. RNA peaks were  
181 manually curated from IGRs and protein-coding gene regions. A read threshold for sRNA  
182 expression was devised for each condition tested based on reads that aligned to the *rpoD* gene  
183 (RpoD sigma factor), since TPM data suggest this gene is consistently expressed across all  
184 conditions. Using this method, putative sRNAs were identified, base ranges approximated, and  
185 sRNAs further characterized with putative promoters by manual searches using the conserved  
186 alphaproteobacterial sigma-70 promoter element, CTTGAC-N<sub>17</sub>-CTATAT [38]. Rho-  
187 independent terminators were identified using ARNold terminator prediction software  
188 (<http://rna.igmors.u-psud.fr/toolbox/arnold/>).

189 Since TPM calculations were done in the context of the total transcriptome and were not  
190 strand-specific, it was necessary to further refine TPM values for *cis*-anti sRNAs. This was done  
191 by considering the TPM value and proportion of the protein-coding gene to which the sRNA was  
192 antisense and subtracting the gene's approximate TPM contribution with the following formula:

$$193 \quad sRNA \text{ Adjusted TPM} = sRNA \text{ Total TPM} - \left[ \frac{\frac{Gene \text{ Total TPM}}{Gene \text{ Length}}}{(Gene \text{ sRNA overlap Length})} \right]$$

194 This was accomplished with a custom python script located in a GitHub repository  
195 ([https://github.com/shawachter/TPM\\_Scripts](https://github.com/shawachter/TPM_Scripts)). After this calculation, sRNAs whose TPMs were  
196 < 300 were considered not expressed for the purposes of the UpSet plot. This TPM value was  
197 chosen because it most accurately reflected the read threshold used in the initial manual sRNA  
198 search. All TPM values were included in the heatmap and determination of condition-specific

199 sRNAs. Differentially-expressed sRNAs were determined by featureCounts [39] and the DESeq2  
200 package of R version 3.4.4 [40]. For DESeq2 analysis, the p-value distribution of the  
201 significantly differentially expressed genes (DEGs) was re-sampled using fdrtools in order to  
202 more accurately achieve the desired null distribution [41]. This effectively made the analysis  
203 more stringent by providing fewer significant DEGs.

204 Infection-specific and sand fly-specific sRNAs were identified based on expression patterns  
205 as described in Results. The IntaRNA 2.0 sRNA target prediction algorithm was used to  
206 determine potential genes regulated by the sRNAs [42]. Only mRNA targets with a predicted  
207 IntaRNA 2.0 p-value  $< 0.01$  were included in the potential targets list. Further targets with False  
208 Discovery Rate (FDR) values of  $< 0.05$  were given special indications since these predicted  
209 bindings were considered especially strong. GO enrichment was performed utilizing the biobam  
210 Blast2GO program in the OmicsBox program suite ([https://www.blast2go.com/blast2go-](https://www.blast2go.com/blast2go-pro/download-b2g)  
211 [pro/download-b2g](https://www.blast2go.com/blast2go-pro/download-b2g)) using functional annotation of the *B. bacilliformis* KC583 genome as the  
212 background [43]. KEGG enrichment was performed using DAVID Bioinformatics Resources  
213 [44].

214 Figures were made using R version 3.4.4 and various Bioconductor packages including  
215 UpSetR [45], gplots (<https://cran.r-project.org/web/packages/gplots/index.html>), ggplot2 [46],  
216 and fdrtool [41]. Raw PNG images were modified into figures using Inkscape  
217 (<https://inkscape.org/release/inkscape-0.92.4/>) and Gimp (<https://www.gimp.org/downloads/>).

## 218 **Identification of transcription start sites**

219 5' RACE analyses of BbgpI and BbsR9 were performed using total RNA from *B. bacilliformis*  
220 shifted to liquid medium at pH 7 using a 5' RACE System kit (Invitrogen; Carlsbad, CA)

221 according to manufacturer's protocols and with gene-specific primers (**S1 Table**). Resulting PCR  
222 products were cloned into pCR2.1-TOPO as instructed (Invitrogen), after which six arbitrary  
223 clones were sequenced with M13 universal primers by Sanger automated sequencing.

#### 224 **Northern blots**

225 Northern blot analyses were carried out using total RNA extracted from *B. bacilliformis* under  
226 the noted conditions. Northern blot probes were synthesized *in vitro* by engineering probe-  
227 specific PCR primers to contain a T7 promoter then utilizing a MAXIscript T7 Transcription kit  
228 (Invitrogen) supplemented with 0.5 mM Bio-16-UTP (Invitrogen). *B. bacilliformis* total RNA (2  
229 µg) was resolved on a 1% denaturing agarose gel for 130 min at 57 V in 1X MOPS running  
230 buffer (Quality Biological; Gaithersburg, MD). The gel was washed in nuclease-free H<sub>2</sub>O for 10  
231 min, followed by another wash in 20X SSC buffer (3M NaCl, 0.3M sodium citrate, pH 7.0) for  
232 15 min. RNA was transferred overnight to a BrightStar-Plus nylon membrane (Ambion) in 20X  
233 SSC via upward capillary transfer. RNA was crosslinked to the membrane using a GS Gene  
234 Linker UV chamber (Bio-Rad; Hercules, CA) at 150 mJ. Membrane pre-hybridization and probe  
235 hybridization were done with a North2South Chemiluminescent Hybridization and Detection Kit  
236 (Thermo Fisher) according to manufacturer's protocol. 50 ng of the appropriate *in vitro*-  
237 transcribed biotin-labeled probe was hybridized to the membrane at 67°C overnight. Membranes  
238 were washed 3 times for 15 min at 67°C in 1X Hybridization Stringency Wash Buffer (Thermo  
239 Fisher), developed, and imaged with a ChemiDoc XRS+ system (Bio-Rad).

#### 240 **qRT-PCR**

241 qRT-PCR was done on cDNA synthesized from 16 ng *B. bacilliformis* total RNA (for each 25 µl  
242 reaction) collected from various conditions using the Luna Universal One-Step RT-qPCR kit  
243 (New England BioLabs; Ipswich, MA) according to the manufacturer. *B. bacilliformis* total RNA

244 was serially diluted and used as a standard curve, while primers targeting the *rpoD* housekeeping  
245 gene were used for normalization of gene expression between conditions. qRT-PCR was  
246 performed on a CFX Connect Real-Time System (Bio-Rad). cDNA from sRNAs of interest was  
247 analyzed for copy number, then divided by the copy number from the *rpoD* gene to achieve the  
248 sRNA transcripts / *rpoD* transcript values.

#### 249 **Mutagenesis and RNA-RNA EMSAs**

250 Mutagenesis of *gcvT*, *nuoF*, and *ftsH* target sequences was carried out *in vitro* using a Q5  
251 mutagenesis kit (New England BioLabs) with specified primers (**S1 Table**). Primers engineered  
252 with a T7 promoter sequence were used to amplify the *gcvT* (-100 to +100), *nuoF* (-86 to +100),  
253 *ftsH* (-100 to +105), RS02100 (-76 to +100), *trmD* (-50 to +100), and *hflK* (-70 to +100) target  
254 sequences, where nucleotide +1 represents the first nucleotide of the protein-coding sequence.  
255 PCR products were cloned into pCR2.1-TOPO as instructed (Invitrogen). Resulting plasmid  
256 DNA was used as the template for Q5 mutagenesis. Q5 clones were sequenced, re-amplified with  
257 T7-engineered primers, and *in vitro* transcribed using the MAXIscript T7 Transcription kit  
258 (Invitrogen) with or without 0.5 mM Bio-16-UTP (Invitrogen), as required. Dose-dependent  
259 RNA-RNA EMSAs were performed as previously described [35] using 2 nM biotin-labeled  
260 BbsR9 and varying concentrations of *in vitro*-transcribed, unlabeled target RNA.

#### 261 **Data availability**

262 Aligned sequencing reads (BAM files) from all RNA-Seq experiments are available at the  
263 Sequencing Read Archive database (accession number PRJNA647605).

#### 264 **Ethics statement**

265 The Institutional Biosafety Committee at the University of Montana granted approval for the  
266 experimental use of human blood (IBC 2019-05). Formal consent was obtained in verbal form  
267 from the blood donor (co-author MFM).

## 268 **Results**

### 269 **Identification of *B. bacilliformis* sRNAs**

270 We first analyzed the total transcriptomic profiles of *B. bacilliformis* following a timed shift  
271 from normal culture conditions (4-d incubation on HIBB plates at 30°C) to various *in vitro*  
272 conditions that mimic the sand fly vector and human host (**Table 1**). Specifically, we controlled  
273 for several environmental variables, including temperature, pH, solid vs. liquid media, and the  
274 presence of a human blood-gas atmosphere. Following quality control analysis of the resulting  
275 RNA-Seq datasets and correlation of variation analysis (**S2 Table**), we discarded replicates that  
276 did not correlate well with others from the same condition. A principle component analysis  
277 (PCA) plot of the remaining RNA-Seq datasets confirmed statistical clustering of biological  
278 replicates (**S1 Fig**).

279

280 **Table 1. Conditions used to prepare *B. bacilliformis* cultures for RNA-Seq experiments.**

Conditions	Medium	Designation	Shift Time	Simulation
pH 7.4, 25°C	HIBB plates	PI25	2 hours	Sand fly ambient temperature
pH 7.4, 30°C	HIBB plates	PI30	2 hours	Sand fly ambient temperature
pH 7.4, 37°C	HIBB plates	PI37	2 hours	Human host
pH 7.4, 37°C with blood gas <sup>a</sup>	HIBB plates	PIBG	2 hours	Human host

pH 6.0, 30°C	HIBB liquid	pH06	2 hours	Sand fly post-blood meal
pH 7.4, 30°C	HIBB liquid	pH07	2 hours	Human host / sand fly blood meal mid-digestion
pH 8.2, 30°C	HIBB liquid	pH08	2 hours	Sand fly initial blood meal
pH 7.4, 37°C with blood gas	HUVECs in EGM-Plus medium	HUVE	24 hours	Human endothelial cell infection
pH 7.4, 37°C	Human blood	HB37	2 hours	Human erythrocyte infection
pH 7.4, 37°C with blood gas	Human blood	HBBG	2 hours	Human erythrocyte infection

281 HIBB, Bacto heart infusion blood agar containing 4% defibrinated sheep blood and 2% sheep  
 282 serum (vol/vol); HUVECs, human umbilical vein endothelial cells; EGM-Plus (Lonza),  
 283 endothelial cell growth medium containing 2% fetal bovine serum and bovine brain extract.

284 <sup>a</sup> Blood gas is comprised of 5% CO<sub>2</sub>, 2.5% O<sub>2</sub>, and 92.5% N<sub>2</sub> at 100% humidity to simulate  
 285 human blood.

286

287 Next, we visualized alignments for each RNA-Seq dataset and manually curated transcript  
 288 peaks that could correspond to novel sRNAs. Peaks were found in intergenic regions (IGRs),  
 289 antisense to annotated genes (*cis*-anti) or as leader RNAs in 5' untranslated regions (UTRs) of  
 290 annotated genes. The peaks were further refined based on proximity to neighboring peaks and a  
 291 threshold read coverage based on expression of a housekeeping gene, *rpoD* (encoding sigma  
 292 factor RpoD). We discovered 160 potential sRNAs, including seven highly-conserved sRNAs of  
 293 other bacteria/alphaproteobacteria (**S3 Table**). Of the 153 other potential sRNAs, 81 were  
 294 located antisense to annotated genes, 57 were encoded in IGRs, and the remaining 15 were

295 potential leader RNAs. Leader RNAs were included in the study because further analysis would  
296 be needed to determine if they are true leader RNAs, stand-alone sRNAs, or perhaps both. We  
297 also identified putative promoter elements for each identified sRNA based on approximated  
298 transcriptional start sites (TSS's). Next, we constructed an UpSet plot to visualize the numbers of  
299 significantly expressed sRNAs shared between various combinations of conditions (**Fig 1**) [47].  
300 Results of this analysis suggested that, while 19 of the 160 identified sRNAs were expressed  
301 regardless of circumstance, the majority of sRNAs were expressed under specific conditions.  
302 Following this, we calculated transcripts per million (TPM) for each sRNA under all ten  
303 conditions in the context of the total transcriptomes (**S4 Table**). TPM is a normalized measure of  
304 gene expression, and although it is not always appropriate to compare TPM values across  
305 different RNA-Seq experiments [48], we constructed a heatmap to get a broad sense of sRNA  
306 expression patterns (**S2 Fig**). These results revealed three distinct clusters of conditions with  
307 similar sRNA expression patterns and allowed us to identify interesting sRNAs for further  
308 characterization.

309

310 **Fig 1. Most *B. bacilliformis* sRNAs are expressed under specific conditions.** An UpSet plot is  
311 shown and displays the number of sRNAs shared among various combinations of conditions  
312 tested. The bar graph to the left indicates the quantity of sRNAs with a TPM >300 under the  
313 conditions shown. The connected nodes indicate shared conditions giving rise to the number of  
314 sRNAs expressed as indicated by the bar graph at the top.

315

316 **Verification of select *B. bacilliformis* sRNAs**

317 Of the 160 putative sRNAs discovered in *B. bacilliformis*, we assigned name designations to 22  
318 of them based on appraisal of general relevance, including six widely-conserved sRNAs, such as  
319 BbtmRNA (*B. bacilliformis* **tmRNA**), and 15 novel *Bartonella*-specific sRNAs. We also gave a  
320 name designation to the *B. bacilliformis* **group I** intron (BbgpI), a group I intron with related  
321 elements previously identified, but not characterized, in other alphaproteobacteria [49]. To  
322 corroborate RNA-Seq expression results and verify sRNA expression, we chose eight novel  
323 sRNAs at random and conducted Northern blot analyses. Results of the Northern blots confirmed  
324 the expression of all eight sRNAs (**Fig 2**).

325

326 **Fig 2. Northern blot analyses confirm expression of eight putative *B. bacilliformis* sRNAs.**

327 Eight separate Northern blots were run under identical experimental conditions (see Materials  
328 and methods). RNA ladders from the respective blots were aligned with each other for  
329 presentation of the resolved total RNA. sRNA designations are shown above each blot. Exposure  
330 times (minutes, m; seconds, s) and origin of the RNA are indicated below each blot.

331

332 We analyzed the differential expression of *B. bacilliformis* genes across the ten tested  
333 conditions by performing relevant pairwise comparisons (**Table 2**) using the DESeq2 package in  
334 R version 3.4.4 [40]. For this analysis, transcriptomes from all ten conditions were compared  
335 simultaneously, while specific, relevant pairwise comparisons were made (**Table 2**). Results  
336 showed the greatest number of significant differentially expressed sRNAs by comparing solid-to-  
337 liquid media and host cell types. Other sRNA candidates were also found to be differentially  
338 regulated by these comparisons (see **S3 Table**). We then utilized quantitative reverse



339 transcription PCR (qRT-PCR) to validate the DESeq2 results. In doing so, we confirmed eleven  
340 sRNAs to be significantly differentially expressed under the relevant conditions (**S3 Fig**).

341

342 **Table 2. DESeq2 Comparisons Made.**

Comparison	Controlled Conditions	No. sRNA DEGs
PI30 <sup>a</sup> vs. PI25	Temperature	0
PI30 <sup>a</sup> vs. PI37	Temperature	2
PI25 <sup>a</sup> vs. PI37	Temperature	0
PI30 <sup>a</sup> vs. pH07	Solid/liquid media	12
pH07 <sup>a</sup> vs. pH08	pH level	0
pH07 <sup>a</sup> vs. pH06	pH level	0
pH06 <sup>a</sup> vs. pH08	pH level	7
PI37 <sup>a</sup> vs. PIBG	Blood gas	1
PIBG <sup>a</sup> vs. HBBG	Solid/liquid media, human/sheep blood	6
PIBG <sup>a</sup> vs. HUVEC	Solid/liquid media, cell type	18
pH07 <sup>a</sup> vs. HUVEC	Temperature, cell type	6
pH07 <sup>a</sup> vs. HB37	Temperature, human/sheep blood	3
HBBG <sup>a</sup> vs. HUVEC	Cell type	17

343 DEGs, significant differentially expressed genes.

344 <sup>a</sup>Reference dataset

345

346 **Condition-specific sRNAs target mRNAs enriched in specific pathways**

347 We grouped several sRNAs based on their expression patterns across the ten conditions tested by  
348 using heatmap comparisons combined with data from the DESeq2 analysis. For example,  
349 multiple sRNAs were significantly and strictly expressed under conditions used to simulate or  
350 actually infect human cells (i.e., PIBG, HUVEC, HB37, and HBBG; see **Table 1**). These sRNAs

351 were classified as human “infection-specific” based on their restricted upregulation (defined by  
352 TPM greater than the mean TPM plus one standard deviation) in at least two of these four  
353 conditions. Based on this definition, we identified 24 infection-specific sRNAs (see **S4 Table**).

354 We were also curious to determine if the predicted mRNA targets of the infection-specific  
355 sRNAs significantly corresponded to particular gene classifications to provide clues regarding  
356 their upregulation under infection-specific conditions. Using gene ontology (GO) and Kyoto  
357 Encyclopedia of Genes and Genomes (KEGG) enrichment analyses and the IntaRNA 2.0 sRNA  
358 target prediction program [42], we determined that the predicted mRNA targets of these sRNAs  
359 (**S5 Table**) were enriched for several GO terms, including protein/amide transport and  
360 nucleotidyltransferase activity (**Fig 3A**). The pool of mRNA targets was also enriched for the  
361 glycerophospholipid/glycerolipid metabolism and nucleotide excision repair KEGG pathways  
362 (**Fig 3B**).

363

364 **Fig 3. Condition-specific sRNA targets are enriched in several GO terms and KEGG**  
365 **pathways. A)** Faceted bar graph of GO enrichment terms for infection-specific and sand fly-  
366 specific sRNA targets. Height of the bars indicates the number of sRNA targets containing that  
367 GO term, while the color displays the significance of enrichment. **B)** Faceted dot plot of KEGG  
368 enrichment terms for infection-specific and sand fly-specific sRNA targets. The enrichment  
369 score refers to the ratio of the number of gene targets corresponding to a particular pathway to  
370 the total number of genes in that pathway. Dot colors represent significance (p-value) of  
371 enrichment for that particular KEGG pathway.

372

373 We also determined that eight sRNAs were only expressed under conditions simulating the  
374 sand fly vector (i.e., PI25, pH06, pH07, and pH08; see **Table 1**). Despite the fact that PI25  
375 clustered separately from pH06, pH07, and pH08 on the heatmap (**S2 Fig**), we included it in the  
376 sand fly-specific conditions due to upregulation of several sRNAs under both pH06/pH08 and  
377 PI25 conditions (BB026-1, BB103-2, BB103-3, and BB124; **S4 Table**). These and other sRNAs  
378 were classified as “sand fly-specific sRNAs” based on their restricted upregulation in at least two  
379 of these four conditions. The predicted mRNA targets of the sand fly-specific sRNAs (**S6 Table**)  
380 were enriched for the flavin adenine dinucleotide (FAD) binding GO term (**Fig 3A**) and the  
381 amino acid biosynthesis KEGG pathway (**Fig 3B**).

382

### 383 **BbgpI is a group I intron that splices *in vivo* and self-splices *in vitro***

384 BB009 was initially identified as a sRNA of interest based on its high expression across multiple  
385 conditions (**S4 Table**). A BLAST search of the BB009 gene sequence (hereafter referred to as  
386 BbgpI) showed that it was highly homologous to a group I intron conserved in several other  
387 alphaproteobacteria and encoded in host tRNA<sub>CCU</sub><sup>Arg</sup> genes [49]. Since *B. bacilliformis* has no  
388 annotated tRNA<sub>CCU</sub><sup>Arg</sup> gene, we initially assumed that BbgpI was encoded in an IGR. However,  
389 such a location would be novel for group I introns, which are selfish genetic elements found in  
390 tRNA, rRNA, and rarely, protein-coding genes (reviewed in [50]).

391 To address this discrepancy, 5' rapid amplification of cDNA ends (5' RACE) was utilized to  
392 determine the 5' end of the putative spliced-out RNA segment. From these results, we  
393 determined that BbgpI was flanked by CCT direct repeats, identical to those produced by the  
394 tRNA<sub>CCU</sub><sup>Arg</sup> alphaproteobacterial group I intron (**S4A Fig**) [49]. Also, the predicted secondary

395 structure of BbgpI possessed conserved group I intron stem structures (**S4B Fig**). Finally, we  
396 scanned the locus and flanking sequences with the tRNAscan-SE 2.0 web server and identified a  
397 tRNA<sub>CCU</sub><sup>Arg</sup> gene (**S4C Fig**), but only when a sequence with BbgpI spliced out was used [51].  
398 Taken together, these results suggest that BbgpI is a member of a conserved,  
399 alphaproteobacterial group I intron family and disrupts an unannotated tRNA<sub>CCU</sub><sup>Arg</sup> gene (locus:  
400 c42404-42711) of *B. bacilliformis*.

401 Although homology and structural results suggested that BbgpI was a group I intron, it  
402 was unclear whether BbgpI was able to self-splice or whether a protein cofactor was required  
403 [49]. To address this question, we examined BbgpI's ribozyme activity *in vitro*. Following *in*  
404 *vitro* transcription, cDNA synthesis, and PCR analysis with the primers shown in **S4A Fig**, we  
405 determined that BbgpI self-splices *in vitro* and is spliced *in vivo* (**Fig 4**), in keeping with other  
406 group I introns.

407

408 **Fig 4. BbgpI self-splices *in vitro* and is spliced *in vivo*.**

409 **A)** PCR analysis of an *in vitro*-transcribed (IVT) region of *B. bacilliformis* (Bb) genomic DNA  
410 (gDNA) containing BbgpI. Ethidium bromide-stained agarose (1%) gels are shown. PCR on the  
411 resulting cDNA using “Nested Primers” (see **S4A Fig**) produced unspliced DNA (450-bp band),  
412 a partially-spliced product of ~390 bp, plus a 218-bp band corresponding to the BbgpI flanking  
413 region where BbgpI self-spliced out (indicated by the red arrow). PCR on a Bb IVT RNA  
414 negative control did not produce product. **B)** As in A) but utilizing cDNA synthesized from *B.*  
415 *bacilliformis* total RNA using “Splice Flank Primers” (see **S4A Fig**). A 308-bp amplicon was  
416 produced from gDNA, whereas a 76-bp band, corresponding to the BbgpI flanking region with

417 BbgpI spliced out, was produced from cDNA generated from total RNA (indicated by the red  
418 arrow). PCR on a Bb total RNA negative control did not produce product.

419

#### 420 **BbsR9 is a sand fly-specific sRNA**

421 BB092 (hereafter referred to as BbsR9) was initially identified as a sRNA of interest due to its  
422 restricted high-level expression under conditions that simulated the sand fly vector (**Table 1, S4**  
423 **Table**). In addition, BbsR9 was found to have well-defined, predicted sigma-70 promoter and  
424 Rho-independent terminator regions, and it was conserved among several other *Bartonella* spp.  
425 (**S3 Table**). To elucidate the BbsR9 gene, the TSS was determined by 5' RACE. These results  
426 showed two possible sites with equal representation among the six clones sequenced (**S5A Fig**).  
427 We therefore wished to determine if two distinct transcripts of BbsR9 were made or if there was  
428 a single, dominant transcript for the sRNA. In addition, we wanted to confirm BbsR9 expression  
429 across the conditions examined. To this end, we set out to determine if BbsR9 would remain  
430 highly expressed in sheep blood shifted to 37°C or if we would see a downregulation of the  
431 sRNA, as in *B. bacilliformis* shifted to human blood at 37°C (HB37/HBBG; see **S4 Table**).  
432 Northern blot analyses showed BbsR9 transcript and, together with the intensity of the signal,  
433 indicated a single, dominant TSS (bolded underlined in **S5A Fig**). Interestingly, we saw a  
434 distinct downregulation of BbsR9 when *B. bacilliformis* was shifted to sheep blood at 37°C  
435 compared to 30°C (**S5B Fig**). This decrease in RNA suggests that BbsR9 is primarily expressed  
436 under conditions that simulate the sand fly vector and not the human host. Taken as a whole,  
437 results of the Northern blots and RNA-Seq suggest that both a liquid medium (PI30 vs. pH07;  
438 see **S4 Table**) and a temperature below 37°C upregulate BbsR9.

439

440 **BbsR9 targets transcripts of *ftsH*, *nuoF*, and *gcvT* in vitro**

441 Since BbsR9 expression was restricted to sand fly-like conditions, we were interested in  
442 characterizing its mRNA targets to shed light on the sRNA's role in regulation. To that end, we  
443 first utilized the TargetRNA2 [52], IntaRNA [42] and CopraRNA [53] algorithms to determine  
444 potential mRNA targets (**Table 3**). From these results, we selected transcripts of *ftsH*, *nuoF*,  
445 *gcvT*, *trmD*, *hflK*, and a predicted DNA response regulator (RS02100) as potential targets for  
446 characterization based on shared predictions between algorithms and the strength of predicted  
447 binding events.

448

449 **Table 3. mRNA targets for BbsR9, as predicted by the indicated algorithms.**

Rank	TargetRNA2	IntaRNA	CopraRNA
1	<b><i>nuoF</i> (0.0001)</b>	<b><i>gcvT</i> (0.0033)</b>	RS06660 (0.0013)
2	RS01360 (0.012)	RS01025 (0.0043)	<b><i>nuoF</i> (0.0103)</b>
3	<i>czrB</i> (0.004)	<b><i>trmD</i> (0.0060)</b>	RS02895 (0.0113)
4	<i>ftsE</i> (0.010)	<b><i>ftsH</i> (0.0071)</b>	<b><i>gcvT</i> (0.0153)</b>
5	RS05725 (0.012)	<b>RS02100 (0.0090)</b>	RS02955 (0.0232)
6	<i>rplX</i> (0.033)	DUF475 (0.0125)	<i>efp</i> (0.0286)
7	<i>flgC</i> (0.043)	Pseudogene (0.0132)	<b><i>ftsH</i> (0.0288)</b>
8	<i>aroP</i> (0.044)	<i>tonB</i> (0.0136)	<b><i>trmD</i> (0.0477)</b>
9		<b><i>hflK</i> (0.0148)</b>	
10		<b><i>nuoF</i> (0.0276)</b>	

450 p-values < 0.05 are indicated in parentheses; bolded gene targets were chosen for further study.

451

452 To demonstrate physical interactions between BbsR9 and the chosen mRNA candidates,  
453 RNA-RNA electrophoretic mobility shift assays (EMSAs) were done using *in vitro*-transcribed

454 BbsR9 and segments of the target mRNAs of interest with their predicted sRNA target regions.  
455 Results of the EMSAs showed that BbsR9 bound mRNAs of *ftsH*, *nuoF*, and *gcvT* *in vitro*, as  
456 judged by the novel hybrid RNA species showing markedly slower migration during gel  
457 electrophoresis (**Fig 5**). Hybrid RNAs were not observed for the other three candidate mRNAs,  
458 suggesting that sRNA binding did not occur.

459

460 **Fig 5. BbsR9 targets transcripts of *ftsH*, *nuoF* and *gcvT* *in vitro*.**

461 RNA-RNA EMSA of biotin-labeled *in vitro*-transcribed BbsR9 binding to *in vitro*-transcribed  
462 mRNA segments of the *ftsH*, *nuoF*, *gcvT*, *trmD*, BARBAKC583\_RS02100 and *hflK* genes. Red  
463 and blue arrows indicate bands corresponding to BbsR9 bound and unbound to target RNAs,  
464 respectively. Base values of the RNA size standard (ladder) are shown on the left.

465

466 We further characterized BbsR9-mRNA interactions by mutagenizing the predicted sRNA-  
467 binding regions of *ftsH*, *nuoF*, and *gcvT* (**Fig 6**). The predicted *ftsH*-binding region was  
468 extensive, so we created two distinct mutants for this target as well as a double-mutant (**Fig 6**).  
469 RNA-RNA EMSAs conducted with the mutagenized target mRNAs showed complete  
470 elimination of BbsR9 binding to all three targets *in vitro* regardless of increasing target quantity  
471 present in the hybridization reaction (**Fig 7**). As expected, wild-type targets showed dose-  
472 dependent hybridization and signal intensity. Interestingly, abrogation of *ftsH* transcript binding  
473 by BbsR9 was only observed with mutation 1 (Mut1) alone or in combination with mutation 2  
474 (Mut2), whereas Mut2 alone did not prevent BbsR9 binding to the RNA (**Fig 7**). In consideration  
475 of the RNA secondary structure predictions and the EMSA results, we conclude that BbsR9

476 primarily targets mRNA transcripts via multiple GC-rich regions of a large, predicted stem-loop  
477 structure (see **Fig 6**) [54].

478

479 **Fig 6. BbsR9 binds its targets through several GC-rich predicted seed regions.**

480 **A)** Mfold secondary structure prediction of BbsR9 ( $\Delta G = -46.9 \text{ J mol}^{-1}$ ) with predicted seed  
481 regions for *ftsH*, *nuoF*, and *gcvT* transcript binding indicated by red, blue, and green lines,  
482 respectively. **B)** Predicted IntaRNA BbsR9 target seed regions of the indicated transcripts. For  
483 the mRNA targets, nucleotide position +1 represents the first nucleotide of the respective start  
484 codon. Mutagenized bases of each mRNA are indicated in red.

485

486 **Fig 7. BbsR9 binds to *ftsH*, *nuoF*, and *gcvT* transcripts via specific GC-rich seed regions.**

487 RNA-RNA EMSAs showing dose-dependency of biotin-labeled BbsR9 binding to wild-type but  
488 not mutated, *in vitro*-transcribed segments of **A-C)** *ftsH*, **D)** *nuoF* and **E)** *gcvT*. Mutated regions  
489 correspond to those shown in **Fig 6B**, and “Dbl” specifies the double *ftsH* mutant. Red and blue  
490 arrows indicate bands corresponding to BbsR9 bound and unbound to target RNAs, respectively.  
491 All reactions contained 2 nM biotin-labeled BbsR9 in addition to increasing amounts of the  
492 indicated targets (0, 2, 4, 8, and 16 nM, respectively).

493

494 **Discussion**



495 In this study, we performed an extensive transcriptomic analysis of *B. bacilliformis* grown *in*  
496 *vitro* then shifted to one of 10 distinct conditions that mimic environments encountered by the  
497 bacterium during its natural life cycle. We chose these conditions in order to control for a variety  
498 of environmental factors that may directly influence expression of certain sRNAs. For example,  
499 temperature (25<sup>o</sup>C, 30<sup>o</sup>C, 37<sup>o</sup>C), pH levels (pH 6, pH 7.4, pH 8.2), solid/liquid substrates, and  
500 presence of a blood-gas atmosphere (5% CO<sub>2</sub>, 2.5% O<sub>2</sub>, and 92.5% N<sub>2</sub> at 100% humidity) were  
501 all examined. In addition, we included RNA-Seq experiments from experimental infections of  
502 low-passage human vascular endothelial cells (HUVEC) and fresh human blood samples (HB37  
503 and HBBG). From these experiments, we discovered 160 sRNAs expressed by *B. bacilliformis* in  
504 at least one of the conditions tested.

505 Although we initially approached sRNA discovery using an automated approach, some  
506 clear-cut sRNAs were missed during the process. This issue led us to manually curate the 10  
507 stranded RNA-Seq alignments, scanning each annotated gene, leader region, and IGR for aligned  
508 reads forming peaks that could represent novel sRNAs. These peaks were required to surpass a  
509 pre-determined read coverage threshold determined independently for each condition based on  
510 reads aligned to the *rpoD* (locus tag: BARBAKC583\_RS04670) gene, which was consistently  
511 expressed across all 10 conditions (TPM ~300; **S4 Table**). We remained consistent by using  
512 *rpoD* as the housekeeping gene in qRT-PCR analyses (**S3 Fig**) and employing a 300 TPM  
513 threshold for the purpose of the UpSet plot (**Fig 1**).

514 The putative sRNAs identified were organized into three categories (IGR, *cis*-anti, or  
515 leader) depending on location of the corresponding sRNA locus. Each sRNA category has  
516 implications for its potential function. For example, IGR sRNAs are likely *trans*-acting with  
517 small seed regions that often bind multiple mRNAs. *Cis*-anti sRNAs most likely target the gene

518 to which they are antisense, so target identification via algorithms such as IntaRNA would not be  
519 useful. Putative leader sRNAs are peaks that were identified sense to and in the 5' UTRs of  
520 protein-coding genes. Although the identified peaks appeared distinct from those within the  
521 actual coding sequence, the possibility remains that these peaks are not *trans*-acting sRNAs.  
522 More likely, these leader RNAs may serve as *cis*-acting regulatory components, like  
523 riboswitches, which are co-transcribed with the downstream protein-coding gene and harbor  
524 regulatory stem-loops that influence translation of the respective transcript [55]. Determining  
525 whether the identified leader sRNAs are *cis*- and/or *trans*-acting elements would require further  
526 experiments such as Northern blots and 5' RACE experiments to see if there is read-through into  
527 the downstream gene.

528 We performed Northern blot analyses on the putative leader sRNAs, BbspeF and BbsR7, and  
529 found that these are likely *cis*-acting leader RNAs, since the RNA sizes suggest read-through  
530 into the downstream gene (**Fig 2**). Northern blot analysis also verified the existence of six other  
531 sRNAs, although some of the results raise additional questions. For example, the presence of  
532 BbsR2 was detected, but the apparent band of ~450 bases is considerably larger than its  
533 predicted 284-base band (see **Fig 2**, **S3 Table**). Although we identified a putative promoter  
534 element for BbsR2, we did not identify a Rho-independent terminator, so it is possible that the  
535 sRNA extends further downstream than predicted. It was also unclear whether BbsR3-1 / BbsR3-  
536 2 represented two distinct sRNAs. However, Northern blot analysis utilizing a probe against  
537 BbsR3-1 confirmed that there was a single transcript produced whose length (~600 bp) was  
538 equal to the sum of the predicted sizes of BbsR3-1 and BbsR3-2, indicating that this locus  
539 probably produces a single sRNA species (**Fig 2**). The BbsR7 blot also requires explanation.  
540 Here, several bands were identified, including smaller bands of ~200 bases and a larger band of

541 ~600 bases. Since BbsR7 is predicted to be a leader sRNA, it is possible that the smaller bands  
542 represent the sRNA being independently expressed, while the larger band may represent BbsR7  
543 being co-transcribed with the downstream gene (BARBAKC583\_RS01695), which is 225 bp  
544 long (**Fig 2**). We also probed in the BbsR11-1 / BbsR11-2 region to determine if the two  
545 corresponding RNA-Seq peaks represented two distinct sRNAs. In this case, the Northern blot  
546 showed a single band that corresponded only to the predicted size of BbsR11-1 (**Fig 2**),  
547 suggesting that the locus harbors two distinct sRNAs. Northern blots for BbgpI and BbsR9  
548 produced single bands (**Fig 2**) that corresponded well to the estimated sizes of their respective  
549 peaks by RNA-Seq.

550         Among the sRNAs analyzed by Northern blot, Bbar45 and BbspeF are intriguing, non-  
551 coding RNA elements worthy of further characterization. Bbar45 belongs to the  $\alpha$ 45 sRNA  
552 family first described in *Sinorhizobium meliloti*, but it is widely conserved in other Rhizobiales  
553 [56]. Functional characterization of sRNAs in the  $\alpha$ 45 family has not been performed, although  
554 the *S. meliloti*  $\alpha$ 45 can be co-immunoprecipitated with Hfq [57]. Since Hfq is an RNA  
555 chaperone that facilitates sRNA-mRNA interactions, we hypothesize that the *S. meliloti*  $\alpha$ 45  
556 sRNA may be *trans*-acting [58]. Here, we confirmed that Bbar45 is independently expressed  
557 from BbspeF, which lies immediately downstream (**Fig 2**). While this observation was  
558 previously observed in *S. meliloti*, it was unclear whether it was the case for other  
559 alphaproteobacteria [56]. Based on Northern blot results showing a transcript >700 bases (**Fig 2**),  
560 BbspeF is likely a leader RNA that is not independently expressed from its downstream gene.  
561 The *speF* leader RNA was initially discovered during a search for alphaproteobacterial  
562 riboswitches and was named for its upstream location relative to the *Bacillus subtilis speF*  
563 ortholog, which codes for an ornithine decarboxylase protein involved in polyamine biosynthesis

564 [59]. However, metabolites of the polyamine biosynthesis pathway of *B. subtilis* were not shown  
565 to bind to the *speF* leader *in vitro*, leaving the element's function unclear [59]. More experiments  
566 are needed to determine the regulatory role of the BbspeF leader as well as the function of the  
567 Bbar45 sRNA in *B. bacilliformis*.

568 An RNA secondary structure prediction of BbsR14 showed two stem-loops with nearly  
569 identical sequences of TTCCTCCTAA. Remarkably, these are anti-Shine-Dalgarno (anti-SD)  
570 motifs most often found in 16S rRNA, where they function in translational initiation. The  
571 presence of SD sequences outside of a ribosome binding site (RBS) is rare, as they are selected  
572 against in the context of mRNAs, since they can cause ribosome stalling due to hybridization  
573 with 16S rRNA [60, 61]. One way in which sRNAs regulate translation is to bind directly to the  
574 RBS to occlude the ribosome and inhibit translational initiation [31]. In most cases, this is  
575 accomplished via a seed region that overlaps the SD sequence and extends up and/or downstream  
576 [62]. The predicted BbsR14 secondary structure displays unique potential seed regions solely  
577 comprised of anti-SD sequences. We speculate that this arrangement could provide opportunities  
578 for indiscriminate translational repression by the BbsR14 sRNA.

579 We also analyzed each of the identified *B. bacilliformis* sRNAs and discovered that BB019,  
580 BB113, and BB125-2 possessed a single anti-SD sequence (CCTCCT). Interestingly, of the four  
581 sRNAs that contain anti-SD sequences, BbsR14 and BB113 were significantly upregulated at  
582 pH08 relative to pH06 (see **S3 Table**). Conditions of pH08 and pH06 were designed to simulate  
583 the initial and late stages of the sand fly after feeding, respectively. Thus, downregulation of  
584 translation may be advantageous for bacterial survival during initial stages within the sand fly's  
585 midgut. As *B. bacilliformis* persists in the sand fly and infection proceeds, "gearing up" for a  
586 subsequent mammalian infection may occur as the insect prepares for another blood meal.

587 Supporting this notion, we also identified 6S RNA as a sand fly-specific sRNA that was  
588 upregulated at pH08 vs. pH06, although not significantly (see **S4 Table**). 6S RNAs function by  
589 binding to and sequestering the RNA polymerase holoenzyme [63]. The resulting global  
590 repression of transcription during the initial stages of sand fly infection and, to a lesser extent,  
591 throughout a sand fly infection, could conceivably promote persistence of *B. bacilliformis* in the  
592 insect.

593 The mRNA target enrichment analyses for potential sand fly and infection-specific  
594 sRNAs provided insight into the regulation of pathways necessary for bacterial survival in these  
595 disparate environments. For example, targets of sand fly-specific sRNAs were significantly  
596 enriched for genes involved in the FAD-binding GO term and the biosynthesis of amino acids  
597 KEGG pathway (**Fig 3**). FAD-binding proteins include a wide array of proteins that participate  
598 in numerous biological processes. Enrichment of these genes may reflect a relatively low  
599 availability of FAD during residence in the sand fly. *B. bacilliformis* encodes a bifunctional  
600 riboflavin kinase/FAD synthetase (BARBAKC583\_RS05700), and although this gene is  
601 relatively lowly expressed in all conditions tested, there is a downregulation of its expression  
602 under sand fly-like conditions (pH07, average TPM = 49.04) compared to human blood  
603 infections (HBBG, average TPM = 84.94). Enrichment of genes involved in the biosynthesis of  
604 amino acids is possibly explained by the likely downregulation of transcription and translation  
605 under sand fly-like conditions, where *B. bacilliformis* enters into a stationary phase that may  
606 promote persistence.

607 The human infection-specific sRNA targets were enriched in multiple GO terms associated  
608 with transferase activities, transporters, and the phospholipid biosynthetic process and KEGG  
609 pathways associated with glycerolipid/glycerophospholipid metabolism and nucleotide excision

610 repair (**Fig 3**). Among these, there is a clear regulation of cell wall constituents during human  
611 infection conditions that would presumably be associated with morphological changes to the  
612 bacterium in the human host or perhaps as a means of expressing outer membrane  
613 proteins/transporters that aid in bacterial growth and replication during infection. This may very  
614 well also be in response to stressors encountered under these conditions, since nucleotide  
615 excision repair also seems to be significantly regulated by infection-specific sRNAs.

616         When analyzing mRNA targets of the infection-specific sRNAs, it was clear that  
617 numerous sRNAs were predicted to target the same mRNA in several cases (see **S5 Table**). For  
618 example, of the 19 presumed *trans*-acting, infection-specific sRNAs, three independently target  
619 BARBAKC583\_RS04310 transcripts, coding for lysylphosphatidylglycerol synthetase; an  
620 enzyme previously shown to augment a pathogen’s defense against host cationic antimicrobial  
621 immune peptides [64]. Additionally, four of the 19 predicted *trans*-acting, infection-specific  
622 sRNAs target BARBAKC583\_RS00395 transcripts, coding for cobaltochelataase subunit CobT,  
623 which is involved in the synthesis of cobalamin (vitamin B<sub>12</sub>), an essential coenzyme for many  
624 biological reactions [65]. It is difficult to ascribe roles to these mechanisms without knowing  
625 whether the sRNA-mediated regulation is positive or negative, although it is worth noting that  
626 redundant targeting is not a result of sRNA duplication, and each predicted binding site on these  
627 transcripts is unique. We hypothesize that redundant regulation of particular mRNAs may serve  
628 to “hyper-regulate” protein production in response to subtle differences in environmental cues.  
629 This kind of redundant regulation of mRNAs from multiple “sibling sRNAs” has been described  
630 in other pathogens, so further research into the function of sibling sRNAs of *B. bacilliformis*  
631 could be fruitful [66].

632 We found conservation of some sRNAs among other alphaproteobacteria species using  
633 discontinuous megaBLAST analysis (**S3 Table**). Unfortunately, we were only able to analyze  
634 IGR and leader sRNAs, since *cis*-anti sRNAs showed broad sequence conservation due to their  
635 close linkage to protein-coding genes. The majority of analyzed sRNAs was unique to *B.*  
636 *bacilliformis*, while the BB036 sRNA group was unique to the KC583 strain of *B. bacilliformis*.  
637 Five other sRNAs were widespread in *Bartonella* spp., including BbsR9 which was characterized  
638 in this study. Conservation of BbsR9 in other *Bartonella* spp. further highlights its potential  
639 importance. Since *Bartonella* spp. are typically transmitted to mammals by various arthropods  
640 (ticks, sand flies, fleas, lice, etc.), it is possible that BbsR9 plays a role in persistence in many  
641 vectors. Seven more sRNAs were found in additional alphaproteobacteria, including ubiquitous  
642 sRNAs like 6S RNA and tmRNA, conserved alphaproteobacteria sRNAs like Bbar45, and the  
643 tRNA<sub>Arg</sub><sup>CCU</sup> group I intron.

644 BbgpI is a member of a tRNA<sub>CCU</sub><sup>Arg</sup> group I intron family first identified in  
645 *Agrobacterium tumefaciens* and later found in other alphaproteobacteria [67, 49]. Group I introns  
646 are selfish genetic elements that insert into tRNAs, rRNAs, and protein-coding genes. Although  
647 group I introns are ribozymes and RNA splicing is auto-catalytic, they sometimes require protein  
648 co-factors for self-splicing *in vitro*, and it is presumed that all group I introns require protein co-  
649 factors to some extent for splicing *in vivo* [50]. Here, we have demonstrated that BbgpI self-  
650 splices *in vitro* and is spliced *in vivo*. Furthermore, we have shown that BbgpI is not located in an  
651 IGR as presumed, but rather within an unannotated tRNA<sub>CCU</sub><sup>Arg</sup> gene. Since the flanking  
652 tRNA<sub>CCU</sub><sup>Arg</sup> gene retains all necessary tRNA domains (see **S4C Fig**), we predict that the tRNA is  
653 functional following intron splicing. This novel tRNA gene might have implications for future  
654 analyses of *B. bacilliformis* involving codon bias, conservation of tRNA genes, amino acid

655 scavenging, etc. Furthermore, this discovery suggests further optimization may be required for  
656 current tRNA scanning algorithms.

657         We also characterized the targeting and molecular interactions of BbsR9, as the sRNA  
658 was only appreciably expressed under pH06, pH07, and pH08 conditions (**S4 Table**). For  
659 reference, these conditions reflect a liquid blood / serum environment at 30°C (**Table 1**) and  
660 simulate the sand fly's midgut following a blood meal. It is interesting to note that the P130  
661 condition is identical to pH07 except that P130 represents a solid medium. Furthermore, Northern  
662 blot analyses indicated that, in addition to the liquid medium requirements, BbsR9 expression  
663 was restricted to temperatures < 37°C (**S5B Fig**). The regulatory mechanisms that facilitate such  
664 an expression pattern warrant further investigation.

665         We verified several mRNA targets of BbsR9 using RNA-RNA EMSAs. Among the targets  
666 were transcripts of the *ftsH*, *nuoF*, and *gcvT* genes. First, *ftsH* codes for the FtsH zinc  
667 metalloprotease; a membrane-anchored, universal protease with various functions. FtsH has been  
668 extensively studied in *E. coli*, where it is the only protease essential for survival [reviewed in  
669 68]. FtsH has also been described as required for regulation of optimal ratios of phospholipids  
670 and lipopolysaccharides in the outer membrane [68]. Whether BbsR9 regulation of *ftsH*  
671 transcripts is involved in bacterial protein turnover and/or modulation of membrane architecture  
672 in the context of the sand fly is unknown, but would be interesting to investigate. Second, the  
673 *nuoF* gene codes for the NADH-quinone oxidoreductase subunit F, a component of the type I  
674 NADH dehydrogenase enzyme and the initial step in the electron transport chain. NuoF is a  
675 component of the peripheral fragment of the NADH dehydrogenase complex and plays a role in  
676 oxidation of NADH to generate a proton motive force [reviewed in 69]. Regulation of *nuoF*  
677 transcripts could conceivably play a role in helping to establish the stationary phase as *B.*



678 *bacilliformis* persists in the sand fly. Finally, we determined that BbsR9 targets transcripts of  
679 *gcvT*, which codes for the glycine cleavage system aminomethyltransferase, GcvT. The glycine  
680 cleavage system responds to high concentrations of glycine, breaking the amino acid down to  
681 CO<sub>2</sub>, ammonia, and NADH [70]. In addition to redox reactions, NADH can be used to produce  
682 energy through cellular respiration. Of note is the potential interplay between sRNA targeting of  
683 *nuoF* and *gcvT* transcripts in this regard. Interestingly, the glycine cleavage system has been  
684 implicated in contributing to bacterial persistence in animal and plant hosts [71]. In fact, *gcvT* is  
685 essential for persistence of a closely-related pathogen, *Brucella abortus*, in its animal host [72].  
686 However, to our knowledge, the role of a glycine cleavage system in pathogen persistence in its  
687 arthropod vector has not been explored, to date. It is conceivable that *B. bacilliformis* utilizes  
688 regulation of *nuoF* and *gcvT* to fine-tune levels of NAD<sup>+</sup>/NADH, thereby contributing to  
689 regulation of metabolism and persistence of the bacterium in the sand fly.

690 This study has provided further insight into the regulation of numerous processes by *B.*  
691 *bacilliformis* in response to conditions encountered in the context of its sand fly vector and  
692 human host. We believe the results provide a strong foundation for future studies examining  
693 sRNA-mediated regulation in *B. bacilliformis* and the regulatory mechanisms required for  
694 vector-host transmission.

695

## 696 **Acknowledgments**

697 The authors wish to thank Patty Langasek and Auguste Dutcher for technical assistance. This  
698 work was supported by NIH grant R21AI128575 (to MFM). RR was supported by NIH grants  
699 AI133023 and DE028409.

700

## 701 **References**

- 702 1. Schultz MG. A history of bartonellosis (Carrión's disease). *Am J Trop Med Hyg.*  
703 1968;17(4):503-15.
- 704 2. Gomes C, Pons MJ, Del Valle Mendoza J, Ruiz J. Carrion's disease: an eradicable  
705 illness? *Infect Dis Poverty.* 2016;5(1):105.
- 706 3. Gray GC, Johnson AA, Thornton SA, Smith WA, Knobloch J, Kelley PW, *et al.* An  
707 epidemic of Oroya fever in the Peruvian Andes. *Am J Trop Med Hyg.* 1990;42(3):215-  
708 21.
- 709 4. Hertig M. Carrión's disease. V. Studies on Phlebotomus as the possible vector. *Proc Soc*  
710 *Exp Biol Med.* 1937;37(3):598-600.
- 711 5. Battisti JM, Lawyer PG, Minnick MF. Colonization of *Lutzomyia verrucarum* and  
712 *Lutzomyia longipalpis* sand flies (Diptera: Psychodidae) by *Bartonella bacilliformis*, the  
713 etiologic agent of Carrión's disease. *PLoS Negl Trop Dis.* 2015;9(10):e0004128.
- 714 6. Maguiña C, Gotuzzo E. Bartonellosis. New and old. *Infect Dis Clin North Am.*  
715 2000;14(1):1-22.
- 716 7. Minnick MF, Anderson BE, Lima A, Battisti JM, Lawyer PG, Birtles RJ. Oroya fever  
717 and verruga peruana: bartonelloses unique to South America. *PLoS Negl Trop Dis.*  
718 2014;8(7):e2919.
- 719 8. Maguiña C, Garcia PJ, Gotuzzo E, Cordero L, Spach DH. Bartonellosis (Carrión's  
720 disease) in the modern era. *Clin Infect Dis.* 2001;33(6):772-9.
- 721 9. Reynafarje C, Ramos J. The hemolytic anemia of human bartonellosis. *Blood.*  
722 1961;17:562-78.

- 723 10. Maguiña C, Guerra H, Ventosilla P. Bartonellosis. Clin Dermatol. 2009;27(3):271-80.
- 724 11. Amano Y, Rumbela J, Knobloch J, Olson J, Kron M. Bartonellosis in Ecuador: serosurvey  
725 and current status of cutaneous verrucous disease. Am J Trop Med Hyg. 1997;57(2):174-  
726 9.
- 727 12. Blazes DL, Mullins K, Smoak BL, Jiang J, Canal E, Solorzano N, *et al.* Novel *Bartonella*  
728 agent as cause of verruga peruana. Emerg Infect Dis. 2013;19(7):1111-4.
- 729 13. Eremeeva ME, Gerns HL, Lydy SL, Goo JS, Ryan ET, Mathew SS, *et al.* Bacteremia,  
730 fever, and splenomegaly caused by a newly recognized *Bartonella* species. N Engl J  
731 Med. 2007;356(23):2381-7.
- 732 14. Ulloa GM, Vásquez-Achaya F, Gomes C, Del Valle LJ, Ruiz J, Pons MJ, *et al.* Molecular  
733 detection of *Bartonella bacilliformis* in *Lutzomyia maranonensis* in Cajamarca, Peru: a  
734 new potential vector of Carrion's disease in Peru? Am J Trop Med Hyg.  
735 2018;99(5):1229-1233.
- 736 15. Birtles RJ, Canales J, Ventosilla P, Alvarez E, Guerra H, Llanos-Cuentas A, *et al.* Survey  
737 of *Bartonella* species infecting intradomicillary animals in the Huayllacallán Valley,  
738 Ancash, Peru, a region endemic for human bartonellosis. Am J Trop Med Hyg.  
739 1999;60(5):799-805.
- 740 16. Hertig M. Phlebotomus and Carrion's disease III. Field studies on *Phlebotomus*. Am J  
741 Trop Med Hyg. 1942;S1-22(4):23-60.
- 742 17. Bentzel DE, Espinosa BJ, Canal E, Blazes DL, Hall ER. Susceptibility of owl monkeys  
743 (*Aotus nancymae*) to experimental infection with *Bartonella bacilliformis*. Comp Med.  
744 2008;58(1):76-80.

- 745 18. Benson LA, Kar S, McLaughlin G, Ihler GM. Entry of *Bartonella bacilliformis* into  
746 erythrocytes. *Infect Immun.* 1986;54(2):347-53.
- 747 19. Scherer DC, DeBuron-Connors I, Minnick MF. Characterization of *Bartonella*  
748 *bacilliformis* flagella and effect of anti-flagellin antibodies on invasion of human  
749 erythrocytes. *Infect Immun.* 1993;61(12):4962-71.
- 750 20. Mitchell SJ, Minnick MF. Characterization of a two-gene locus from *Bartonella*  
751 *bacilliformis* associated with the ability to invade human erythrocytes. *Infect Immun.*  
752 1995;63(4):1552-62.
- 753 21. Coleman SA, Minnick MF. Establishing a direct role for the *Bartonella bacilliformis*  
754 invasion-associated locus B (IalB) protein in human erythrocyte parasitism. *Infect*  
755 *Immun.* 2001;69(7):4373-81.
- 756 22. Hendrix LR. Contact-dependent hemolytic activity distinct from deforming activity of  
757 *Bartonella bacilliformis*. *FEMS Microbiol Lett.* 2000;182(1):119-24.
- 758 23. Verma A, Ihler GM. Activation of Rac, Cdc42 and other downstream signaling  
759 molecules by *Bartonella bacilliformis* during entry into human endothelial cells. *Cell*  
760 *Microbiol.* 2002;4(9):557-69.
- 761 24. Garcia FU, Wojta J, Broadley KN, Davidson JM, Hoover RL. *Bartonella bacilliformis*  
762 stimulates endothelial cells *in vitro* and is angiogenic *in vivo*. *Am J Pathol.*  
763 1990;136(5):1125-35.
- 764 25. Minnick MF, Smitherman LS, Samuels DS. Mitogenic effect of *Bartonella bacilliformis*  
765 on human vascular endothelial cells and involvement of GroEL. *Infect Immun.*  
766 2003;71(12):6933-42.

- 767 26. Hicks LD, Minnick MF. Human vascular endothelial cells express epithelial growth  
768 factor in response to infection by *Bartonella bacilliformis*. PLoS Negl Trop Dis.  
769 2020;14(4):e0008236.
- 770 27. Caceres AG. Geographic distribution of *Lutzomyia verrucarum* (Townsend, 1913)  
771 (Diptera, Psychodidae, Phlebotominae), vector of human bartonellosis in Peru. Rev Inst  
772 Med Trop Sao Paulo. 1993;35(6):485-90.
- 773 28. Garreaud RD. The Andes climate and weather. Adv. Geosci. 2009;22:3-11.
- 774 29. Santos VC, Araujo RN, Machado LA, Pereira MH, Gontijo NF. The physiology of the  
775 midgut of *Lutzomyia longipalpis* (Lutz and Neiva 1912): pH in different physiological  
776 conditions and mechanisms involved in its control. 2008;211(Pt 17):2792-8.
- 777 30. Gontijo NF, Almeida-Silva S, Costa FF, Mares-Guia ML, Williams P, Melo MN.  
778 *Lutzomyia longipalpis*: pH in the gut, digestive glycosidases, and some speculations upon  
779 *Leishmania* development. Exp Parasitol. 1998;90(3):212-9.
- 780 31. Carrier MC, Lalaouna D, Massé E. Broadening the definition of bacterial small RNAs:  
781 characteristics and mechanisms of action. Annu Rev Microbiol. 2018;72(1):141-161.
- 782 32. Sledjeski DD, Gupta A, Gottesman S. The small RNA, DsrA, is essential for the low  
783 temperature expression of RpoS during exponential growth in *Escherichia coli*. EMBO J.  
784 1996;15(15):3993-4000.
- 785 33. Wang L, Yang G, Qi L, Li X, Jia L, Xie J, *et al.* A novel small RNA regulates tolerance  
786 and virulence in *Shigella flexneri* by responding to acidic environmental changes. Front  
787 Cell Infect Microbiol. 2016;6:24.
- 788 34. Tu N, Carroll RK, Weiss A, Shaw LN, Nicolas G, Thomas S, *et al.* A family of genus-  
789 specific RNAs in tandem with DNA-binding proteins control expression of the *badA*

- 790 major virulence factor gene in *Bartonella henselae*. *Microbiologyopen*.  
791 2017;6(2):e00420.
- 792 35. Wachter S, Bonazzi M, Shifflett K, Moses AS, Raghavan R, Minnick MF. A CsrA-  
793 binding, *trans*-acting sRNA of *Coxiella burnetii* is necessary for optimal intracellular  
794 growth and vacuole formation during early infection of host cells. *J Bacteriol*.  
795 2019;201(22):e00524-19.
- 796 36. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, *et al*. The sequence  
797 alignment/map (SAM) format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9.
- 798 37. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA. Artemis: an integrated  
799 platform for visualization and analysis of high-throughput sequence-based experimental  
800 data. *Bioinformatics*. 2012;28(4):464-9.
- 801 38. MacLellan SR, MacLean AM, Finan TM. Promoter prediction in the rhizobia.  
802 *Microbiology*. 2006;152(Pt 6):1751-63.
- 803 39. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for  
804 assigning sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923-930.
- 805 40. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for  
806 RNA-seq data with DESeq2. *Genome Biol*. 2014;15(12):550.
- 807 41. Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false  
808 discovery rates. *Bioinformatics*. 2008;24(12):1461-62.
- 809 42. Mann M, Wright PR, Backofen R. IntaRNA 2.0: enhanced and customizable prediction  
810 of RNA-RNA interactions. *Nucleic Acids Res*. 2017; 45(W1): W435-W439.

- 811 43. Götz S, García-Gómez JM, Terol J, Williams TD, Nagaraj SH, Nueda MJ, *et al.* High-  
812 throughput functional annotation and data mining with the Blast2GO suite. *Nucleic Acids*  
813 *Res.* 2008;36(10):3420-35.
- 814 44. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large  
815 gene lists using DAVID bioinformatics resources. *Nat Protoc.* 2009;4(1):44-57.
- 816 45. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of  
817 intersecting sets and their properties. *Bioinformatics.* 2017;33(18):2938-2940.
- 818 46. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. 1<sup>st</sup> ed. New York: Springer-  
819 Verlag; 2016.
- 820 47. Lex A, Gehlenborg N, Strobel H, Vuillemot R, Pfister H. UpSet: Visualization of  
821 intersecting sets. *IEEE Trans Vis Comput Graph.* 2014;20(12):1983-92.
- 822 48. Li B, Ruotti V, Stewart RM, Thomson JA, Dewey CN. RNA-Seq gene expression  
823 estimation with read mapping uncertainty. *Bioinformatics.* 2010;26(4):493-500.
- 824 49. Paquin B, Heinfling A, Shub DA. Sporadic distribution of tRNA(Arg)CCU introns  
825 among alpha-purple bacteria: evidence for horizontal transmission and transposition of a  
826 group I intron. *J Bacteriol.* 1999;181(3):1049-53.
- 827 50. Hausner G, Hafez M, Edgell DR. Bacterial group I introns: mobile RNA catalysts. *Mob*  
828 *DNA.* 2014;5(1):8.
- 829 51. Chan PP, Lowe TM. tRNAscan-SE: searching for tRNA genes in genomic sequences.  
830 *Methods Mol Biol.* 2019;1962:1-14.
- 831 52. Kery MB, Feldman M, Livny J, Tjaden B. TargetRNA2: identifying targets of small  
832 regulatory RNAs in bacteria. *Nucleic Acids Res.* 2014 Jul 1; 42(W1):W124-W129.

- 833 53. Wright PR, Georg J, Mann M, Sorescu DA, Richter AS, Lott S, *et al.* CopraRNA and  
834 IntaRNA: predicting small RNA targets, networks and interaction domains. *Nucleic*  
835 *Acids Res.* 2014 Jul 1; 42(W1):W119-W23.
- 836 54. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic*  
837 *Acids Res.* 2003;31(13):3406-15.
- 838 55. Pavlova N, Kaloudas D, Penchovsky R. Riboswitch distribution, structure, and function  
839 in bacteria. *Gene.* 2019;708:38-48.
- 840 56. del Val C, Romero-Zaliz R, Torres-Quesada O, Peregrina A, Toro N, Jiménez-Zurdo JI.  
841 A survey of sRNA families in  $\alpha$ -proteobacteria. *RNA Biol.* 2012;9(2):119-129.
- 842 57. Torres-Quesada O, Oruezabal RI, Peregrina A, Jofré E, Lloret Javier, Rivilla R, *et al.* The  
843 *Sinorhizobium meliloti* RNA chaperone Hfq influences central carbon metabolism and  
844 the symbiotic interaction with alfalfa. *BMC Microbiol.* 2010;10:71.
- 845 58. Updergrove TB, Zhang A, Storz G. Hfq: The flexible RNA matchmaker. *Curr Opin*  
846 *Microbiol.* 2016;30:133-138.
- 847 59. Corbino KA, Barrick JE, Lim J, Welz R, Tucker BJ, Puskarz I, *et al.* Evidence for a  
848 second class of S-adenosylmethionine riboswitches and other regulatory RNA motifs in  
849 alpha-proteobacteria. *Genome Biol.* 2005;6(8):R70.
- 850 60. Li G-W, Oh E, Weissman JS. The anti-Shine-Dalgarno sequence drives translational  
851 pausing and codon choice in bacteria. *Nature.* 2012;484(7395):538-41.
- 852 61. Diwan GD, Agashe D. The frequency of internal Shine-Dalgarno-like motifs in  
853 prokaryotes. *Genome Biol Evol.* 2016;8(6):1722-33.
- 854 62. Massé E, Gottesman S. A small RNA regulates the expression of genes involved in iron  
855 metabolism in *Escherichia coli*. *Proc Natl Acad Sci U S A.* 2002;99(7):4620-5.



- 856 63. Wassarman KM. 6S RNA, a global regulator of transcription. *Microbiol Spectr.*  
857 2018;6(3):10.1128/microbiolspec.RWR-0019-2018.
- 858 64. Ernst CM, Staubitz P, Mishra NN, Yang S, Hornig G, Kalbacher H, *et al.* The bacterial  
859 defending resistance protein MprF consists of separable domains for lipid lysinylation  
860 and antimicrobial peptide repulsion. *PLoS Pathog.* 2009;5(11):e1000660.
- 861 65. Banerjee R, Ragsdale SW. The many faces of vitamin B12: catalysis by cobalamin-  
862 dependent enzymes. *Annu Rev Biochem.* 2003;72:209-47.
- 863 66. Caswell CC, Oglesby-Sherrouse AG, Murphy ER. Sibling rivalry: related bacterial small  
864 RNAs and their redundant and non-redundant roles. *Front Cell Infect Microbiol.*  
865 2014;4:151.
- 866 67. Reinhold-Hurek B, Shub DA. Self-splicing introns in tRNA genes of widely divergent  
867 bacteria. *Nature.* 1992;357(6374):173-6.
- 868 68. Bittner LM, Arends J, Narberhaus F. When, how, and why? Regulated proteolysis by the  
869 essential FtsH protease in *Escherichia coli*. *Biol Chem.* 2017;398(5-6):625-635.
- 870 69. Falk-Krzesinski HJ, Wolfe AJ. Genetic analysis of the *nuo* locus, which encodes the  
871 proton-translocating NADH dehydrogenase in *Escherichia coli*. *J Bacteriol.*  
872 1998;180(5):1174-84.
- 873 70. Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction  
874 mechanism, physiological significance, and hyperglycemia. *Proc Jpn Acad Ser B Phys*  
875 *Biol Sci.* 2008;84(7):246-63.
- 876 71. Vereecke D, Cornelis K, Temmerman W, Holsters M, Goethals K. Versatile persistence  
877 pathways for pathogens of animals and plants. *Trends Microbiol.* 2002;10(11):485-8.

878 72. Hong PC, Tsolis RM, Ficht TA. Identification of genes required for chronic persistence  
879 of *Brucella abortus* in mice. *Infect Immun.* 2000;68(7):4102-7.

880

## 881 **Supporting information**

882 **S1 Fig. *B. bacilliformis* RNA-Seq PCA plot.** Axes indicate the percentage of total variance that  
883 can be accounted for by two principle components. Colored dots indicate the retained biological  
884 replicates of the RNA-Seq analyses, and their distance apart is representative of overall  
885 relatedness in gene expression profiles. Experimental conditions are shown on the right.

886 **S2 Fig. *B. bacilliformis* sRNAs group into specific expression patterns.** Heatmap of *B.*  
887 *bacilliformis* sRNA TPMs across the tested conditions (shown at the bottom). sRNAs group  
888 vertically based on similarity in expression patterns. Conditions group horizontally based on  
889 similarity in overall expression patterns. The  $\log_{10}$  of the TPM value for each sRNA is indicated  
890 by a color gradient.

891 **S3 Fig. qRT-PCR confirmation of differential expression of several identified sRNAs.**  
892 Faceted bar graph displaying the number of sRNA transcripts / *rpoD* transcript for select,  
893 differentially-expressed sRNAs and BB024, which was not shown to be differentially expressed.  
894 The condition / source of the total RNA is noted on the x-axis. Significance was determined by  
895 students t-test (N = 9; \* =  $p < 0.05$ , \*\* =  $p < 0.01$ , \*\*\* =  $p < 0.001$ ).

896 **S4 Fig. BbgpI is a group I intron inserted into an unannotated tRNA<sup>CCU</sup><sup>Arg</sup> gene of *B.***  
897 *bacilliformis*. **A)** Nucleotide sequence of BbgpI (bolded and underlined) and flanking  
898 chromosomal regions. Primer binding sites used for *in vitro* transcription (IVT) and PCR assays

899 designed to show splicing of BbgpI *in vitro* and *in vivo* are indicated. **B)** Sequence of BbgpI  
900 outlining the conserved, characteristic stem structures (P1 to P9) with putative base pairings  
901 highlighted in green and yellow. Nucleotides predicted to participate in base pairing are bolded  
902 and underlined. **C)** Sequence coding for the tRNA<sub>CCU</sub><sup>Arg</sup> immediately flanking BbgpI. The two  
903 bolded underlined nucleotides represent the ends of the spliced out BbgpI. Conserved tRNA  
904 features are also outlined.

905 **S5 Fig. BbsR9 is a sand fly-specific sRNA.** **A)** Nucleotide sequence of the *bbsR9* gene with  
906 predicted promoter elements and Rho-independent terminator plus experimentally-determined  
907 TSS's, highlighted in various colors or underlined, respectively. An asterisk indicates the  
908 alternative TSS found by 5' RACE analysis. **B)** Northern blot analysis of BbsR9 expression  
909 under the indicated conditions. The RNA ladder (2 min exposure) and resolved total RNA  
910 samples (30s exposure) were from the same blot but imaged using different exposure times.

911 **S1 Table. Bacterial strains, primers, and plasmids used in the study.**

912 **S2 Table. Quality control results for *B. bacilliformis* RNA-Seq analyses.**

913 **S3 Table. Putative sRNAs identified in *B. bacilliformis* by RNA-Seq analyses.**

914 **S4 Table. Average TPMs of identified *B. bacilliformis* sRNAs.**

915 **S5 Table. Predicted IntaRNA targets of *B. bacilliformis* infection-specific sRNAs.** An “X”  
916 indicates transcripts of the indicated gene to which the sRNA is predicted to bind ( $p < 0.01$ ).  
917 Targets with a FDR  $< 0.05$  are indicated with a red “X”.

918 **S6 Table. Predicted IntaRNA targets of *B. bacilliformis* sand fly-specific sRNAs.** An “X”

919 indicates transcripts of the indicated gene to which the sRNA is predicted to bind ( $p < 0.01$ ).

920 Targets with a FDR  $< 0.05$  are indicated with a red “X”.

921




Figure 2

**A**

bioRxiv preprint doi: <https://doi.org/10.1101/2020.08.04.235903>; this version posted August 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



**B**

Figure 4




Figure 5





Figure 1



A

## GO Enrichment of sRNA Targets



B

## KEGG Enrichment of sRNA Targets





Figure 3

A

bioRxiv preprint doi: <https://doi.org/10.1101/2020.08.04.235903>; this version posted August 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



B




Figure 6




Figure 7